This filing details the ownership of securities by John Lawler, Chief Development Officer of Chemomab Therapeutics Ltd. (CMMB). The filing, submitted on April 10, 2026, covers the period ending March 18, 2026. It includes information on both derivative and non-derivative holdings. Lawler directly owns various stock opt...

This filing reports a change in beneficial ownership of securities for Peter Ashley Marks, a director at ALTERITY THERAPEUTICS LTD. The changes involve both derivative and non-derivative holdings. Specifically, there are listed options expiring on February 26, 2027, and unlisted options expiring on December 30, 2027. T...

This filing is a Form 3, which reports initial beneficial ownership of securities, by George Adi Mor, Chief Executive Officer and Director of Chemomab Therapeutics Ltd. The filing details holdings of American Depositary Shares (ADS) both directly and indirectly, including those held by his spouse. It also outlines vari...

This Form 3 filing discloses the initial statement of beneficial ownership of securities by Alan Moses, a director of Chemomab Therapeutics Ltd. (CMMB). The filing reveals Moses holds six separate stock option grants to purchase American Depositary Shares, with exercise prices ranging from $2.14 to $109.04 per share. T...

This filing is an exhibit detailing a Power of Attorney granted by Martin Patrick Murphy, a director at Century Therapeutics, Inc. (IPSC). The document, dated December 9, 2025, and effective April 10, 2026, appoints Brent Pfeiffenberger, Douglas Carr, and Gregory Russotti as attorneys-in-fact. They are authorized to ex...